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Abstract
Background and Aims: Inflammatory bowel diseases (IBDs) are heterogeneous disorders with 
complex aetiology. Quantitative genetic studies suggest that only a small proportion of the disease 
variance observed in IBD is accounted for by genetic variation, indicating a potential role for 
differential epigenetic regulation in disease aetiology. The aim of this study was to assess genome-
wide DNA methylation changes specifically associated with ulcerative colitis (UC), Crohn’s disease 
(CD) and IBD activity.
Methods: DNA methylation was quantified in peripheral blood mononuclear cells (PBMCs) from 149 
IBD cases (61 UC, 88 CD) and 39 controls using the Infinium HumanMethylation450 BeadChip. Technical 
and functional validation was performed using pyrosequencing and the real-time polymerase chain 
reaction. Cross-tissue replication of the top differentially methylated positions (DMPs) was tested in 
colonic mucosa tissue samples obtained from paediatric IBD cases and controls.
Results: A total of 3196 probes were differentially methylated between CD cases and controls, 
while 1481 probes were differentially methylated between UC cases and controls. There was 
considerable (45%) overlap between UC and CD DMPs. The top-ranked IBD-associated PBMC 
differentially methylated region (promoter region of TRIM39-RPP2) was also significantly 
hypomethylated in colonic mucosa from paediatric UC patients. In addition, we confirmed TRAF6 
hypermethylation using pyrosequencing and found reduced TRAF6 gene expression in PBMCs 
of IBD patients.
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Conclusions: Our data provide new insights into differential epigenetic regulation of genes and 
molecular pathways, which may contribute to the pathogenesis and activity of IBD.
Key Words:  Epigenetics; inflammatory bowel disease; DNA methylation
1. Introduction
The inflammatory bowel diseases (IBDs) Crohn’s disease (CD) and 
ulcerative colitis (UC) are chronic inflammatory conditions of the 
gastrointestinal tract. Inflammatory bowel disease is a heterogeneous 
disorder resulting from a complex interplay between genetic varia-
tion, intestinal microbiota, the host immune system and environmen-
tal factors. Genome-wide association studies (GWAS) have identified 
over 160 IBD susceptibility gene loci.1 However, only a small propor-
tion of disease variance (13.6% for CD and 7.5% for UC) observed in 
IBD is accounted for by IBD-associated genetic variants,1,2 indicating 
a role for non-genetic factors in disease aetiology. Moreover, epidemi-
ological studies have identified associations between environmental 
factors3,4 and subsequent risk for one or both IBD sub-phenotypes.
The importance of epigenetic processes acting to developmen-
tally regulate gene expression via modifications to DNA, histone 
proteins and chromatin in complex disease phenotypes is becom-
ing increasingly apparent.5 Epigenetic modifications, such as DNA 
methylation, are hypothesized to have a role in the immune dys-
function phenotype associated with IBD as they are influenced 
by certain environmental factors (e.g. smoking6 and diet7) known 
to be associated with inflammatory diseases.3,4 DNA methylation 
refers to the addition of a methyl group to the carbon at position 
5 of the cytosine ring, resulting in 5-methylcytosine, and is a key 
regulatory mechanism of gene transcription.8 Recent research has 
implicated gene-specific changes in DNA methylation in the patho-
genesis of IBD.9,10,11,12 For example, two recent studies11,12 used the 
HumanMethylation27 BeadChip microarray to identify differential 
DNA methylation at immune-related loci (e.g. TNFSF4, TNFSF12 
and IL‐21R), including previously recognized IBD susceptibility 
genes (e.g. ICAM3 and IL8RB). Moreover, two recent genome-wide 
DNA methylation studies that assessed changes in colonic mucosa in 
treatment-naive paediatric IBD13 and childhood-onset CD14 identi-
fied a number of disease-associated methylation changes at various 
genetic loci, including miR21 and the HLA region. However, the 
majority of studies examining DNA methylation changes associ-
ated with IBD have primarily focused on candidate immune-related 
genes9,10 and/or studied one IBD subtype.11,14 The aim of the current 
study was to assess genome-wide DNA methylation changes using 
the HumanMethylation450 BeadChip array in peripheral blood 
obtained from adult IBD patients and to examine DNA methyla-
tion changes associated with disease activity. The identification of 
molecular pathways with differential epigenetic regulation in the 
peripheral blood of IBD patients would provide novel insights into 
disease pathogenesis and identification of potential biomarkers that 
could facilitate patient management.15
2. Methods
2.1. Study population
Patients with IBD (n = 150, median age 35 years, 83 male) attend-
ing a university teaching hospital between July 2011 and November 
2013 were enrolled in this study. Participants completed a ques-
tionnaire regarding their clinical history and donated a blood sam-
ple. Clinical data, including biologic use, height and weight were 
documented (Supplementary Table S1). The Harvey–Bradshaw 
index or partial Mayo score, radiology, laboratory investigations, 
endoscopy and histology were used as appropriate to form a phy-
sician’s global assessment of disease activity. For further details 
see Supplementary Table S1. Forty individuals without a history 
of inflammatory disorders were recruited via an article placed in 
a national newspaper, an advertisement email sent to staff at St 
Vincent’s University hospital and University College Dublin, and 
from hospital patients without infectious or inflammatory diseases. 
Exclusion criteria for controls included those aged under 18 or over 
70, those with self-reported acute infection, virus or other illness 
affecting the inflammatory system, chronic physical diseases with 
known inflammatory or gastroenterological components (e.g. IBD, 
irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis or 
other autoimmune disorder). Individuals reporting use of medica-
tions affecting the inflammatory system, such as biologic agents or 
steroids, those with cardiac diseases or on cardiac medications and 
pregnant females were also excluded. Controls and IBD patients 
did not differ significantly with respect to gender, smoking, age and 
body mass index (BMI) (p > 0.05 for all comparisons). However, CD 
patients were younger than controls (p = 0.003). All samples were 
corrected for age during the statistical analyses. Ethical approval was 
obtained from St Vincent’s University Hospital Research and Ethics 
Committee.
Peripheral blood mononuclear cells (PBMCs) were isolated by 
density gradient centrifugation. DNA was extracted using a DNAeasy 
kit following the manufacturer’s protocol (Qiagen, Valencia, CA).
2.2. DNA methylation profiling
Genomic DNA (500 ng) was treated with sodium bisulphite using the 
EZ-96 DNA Methylation Kit (Zymo Research, CA, USA) following the 
manufacturer’s protocol. DNA methylation was quantified using the 
Infinium HumanMethylation450 BeadChip (Illumina, Inc., San Diego, 
CA) as previously described.16 Samples were randomized on the array 
with respect to disease status to avoid batch effects. GenomeStudio 
software (Illumina, Inc.) was used to extract signal intensities for each 
probe and perform initial quality control. Further quality control 
checks, quantile normalization and separate background adjustment 
of methylated and unmethylated intensities of type I and II probes were 
undertaken using the dasen function in the R wateRmelon package 
(available from www.bioconductor.org).16 Samples with 1% of sites 
with a detection p value <0.01 or a bead count <3 in 1% of sam-
ples (n = 2) were removed from the analysis. Non-specific probes and 
probes with known single-nucleotide polymorphisms ±10 base pairs 
(bp) from the single base extension site were removed.17,18 Batch effects 
were controlled for using the ComBAT function19 in the ChAMP R 
package.20 The final analyses included 430 821 probes, and 188 sam-
ples (149 IBD cases [88 CD and 61 UC], 39 controls) passed our strin-
gent quality control filter. Probes on the X and Y chromosomes were 
used to confirm the sex of the sample.
2.3. Estimating differential cell counts
Cellular heterogeneity is known to be a major potential con-
founder in epigenomic studies.21 Hence, differential cell counts for 
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each individual were estimated using the Advanced Analysis Blood 
option of the online methylation age calculator (http://labs.genet-
ics.ucla.edu/horvath/dnamage/).22 Cell count estimates for CD4+ 
T cells and B cells were calculated using a previously published 
algorithm.23 The distribution of cell types for each sample was 
inferred based on DNA methylation signatures of the constitu-
ent cell types. In addition, naive CD8+ T cells and CD8+CD28–
CD45RA– T cells were estimated using a method developed by 
Horvath.22 A total of 4 different cell types, including CD4+ T cells, 
naive CD8+ T cells and CD8+CD28–CD45RA– T cells and B cells, 
were estimated.
2.4. Data analyses of genome-wide DNA 
methylation
Statistical analyses were performed using R Statistical Package 
3.1.1. The β value is a ratio between methylated probe intensity 
and total probe intensities (sum of methylated and unmethyl-
ated probe intensities) and ranges from 0 to 1. Although β values 
exhibit heteroscedasticity for highly methylated or unmethylated 
CpG sites compared with M values, they have a more intuitive bio-
logical interpretation and thus were used in this study.24 Linear 
regression was used to examine differences in DNA methylation 
scores (reported as change in β values [∆β]) between CD cases and 
controls, UC cases and controls and active IBD vs inactive disease 
at each CpG site, whilst controlling for potential confounders (age, 
gender, smoking, BMI and estimated cellular composition). Probes 
were ranked according to p value and Q–Q were plots examined 
(Supplementary Figure 1). The p values were adjusted for multi-
ple testing using a stringent Bonferroni correction. Global DNA 
methylation levels (calculated by averaging across all probes on 
the 450K array after adjusting for age, gender, smoking, BMI and 
cellular heterogeneity) were compared between cases and controls 
using an independent t test. Region-level analysis was performed 
using Comb-p software25 to group ≥4 spatially correlated CpGs 
in an 80-bp sliding window. Comb-p performs a Stouffer–Liptak 
correction on probes by assessing its neighbours within 80 bases, 
as weighted by their observed correlation. Following this, puta-
tive regions were identified by seeding on single probes with a 
Bonferroni-adjusted p value less than 1e–4 with extension, provid-
ing it finds another probe with an adjusted p value less than 1e–4 
within 80 bases, as previously described.22
2.5. Gene ontology term enrichment analysis
Gene ontology (GO) term enrichment analysis was performed on 
genes annotated (Illumina UCSC gene annotation) to Bonferroni-
significant differentially methylated positions (DMPs) identified in 
each analysis (UC vs controls and CD vs controls) using the R pack-
age GOseqv1.18.26 GOseq was used to correct for the number of 
Illumina 450K probes in each gene during GO term enrichment anal-
ysis. The number of probes per gene was calculated in our final data-
set to create a probability weighting function, which was then used 
in the GO term enrichment analysis. For this analysis a less stringent 
multiple testing correction was applied (Benjamini–Hochberg false 
discovery rate [FDR]27) to identify significantly enriched GO terms 
(adjusted p values <0.05).
2.6. Bisulphite pyrosequencing
Technical validation of the 450K DNA methylation results was 
performed by bisulphite-pyrosequencing an amplicon spanning 
the TRAF6 CpG site, cg01476222. Pyrosequencing was performed 
on 181 bisulphite-modified DNA samples from our original 
cohort by Epigendx (Hopkinton, MA). Seven samples had insuf-
ficient remaining bisulphite-modified DNA. Samples were ampli-
fied by the bisulphite–polymerase chain reaction (PCR) (HotStar 
Taq Polymerase, Qiagen) and sequenced using the Pyrosequencing 
PSQ96 HS System (Qiagen) with an assay developed by Epigendx. 
The percentage of methylation was calculated for each CpG site as 
methylated cytosine divided by the sum of methylated and unmeth-
ylated cytosines. Correlation between DNA methylation levels 
at cg01476222 CpG sites estimated by pyrosequencing and the 
Illumina 450K BeadChip array was calculated using Spearman’s 
rank correlation coefficient.
2.7. Tumour necrosis factor receptor-associated 
factor 6 gene expression
RNA was extracted from the PBMCs of IBD patients (n = 63) and 
controls (n  =  20) using an E.Z.N.A.® RNA Isolation Kit (VWR, 
Radnor, PA) and converted to cDNA (OmniScript, Qiagen) follow-
ing the manufacturer’s instructions. Expression of the tumour necro-
sis factor (TNF) receptor-associated factor 6 gene (TRAF6) was 
measured using a Taqman Gene Expression Assay, Hs00371512_g1, 
with 18s as an endogenous control (Hs99999901_s1) (Applied 
BioSystems, Foster City, CA) as directed by the manufacturer on 
a LightCycler 480 system (Roche Diagnostics, Indianapolis, IN). 
TRAF6 gene expression was expressed as ∆Ct relative to the levels of 
18s. A non-parametric Mann–Whitney U test was used to examine 
mean ∆Ct values between groups.
2.8. Colonic mucosa DNA methylation data
Colonic mucosa tissue samples were obtained from treatment-
naive paediatric IBD cases (15 CD and 9 UC) and controls 
(n = 22). Samples were recruited from the paediatric gastroenter-
ology tissue bank of the Pediatric Inflammatory Bowel Disease 
Consortium Registry of the Baylor College of Medicine (BCM) 
and MassGeneral Hospital for Children, as described in detail else-
where.13 Genomic DNA was isolated from colonic mucosal biop-
sies using a standard QIAamp DNA Mini Kit (Qiagen, Valencia, 
CA). Treatment-naive IBD cases were diagnosed based upon 
clinical, biochemical and histological characteristics. DNA meth-
ylation was quantified using the Infinium HumanMethylation450 
BeadChip as described above. The R Bioconductor minfi pack-
age28 was used to generate β values normalized to internal control 
probes and corrected for probe type I  or II. The minfi package 
dmpFinder function was used to identify DMPs between controls 
and CD- or UC-affected individuals. Further details can be found 
elsewhere.13
3. Results
3.1. Site-specific DNA methylation differences are 
associated with IBD
We assessed genome-wide patterns of DNA methylation in IBD sub-
types CD and UC compared with controls. No difference in overall 
mean DNA methylation (calculated by averaging across all probes 
on the 450K array) was observed when either CD or UC was com-
pared with controls (p = 0.34 and p = 0.49, respectively), indicating 
that neither CD nor UC is associated with global changes in DNA 
methylation. In contrast, DNA methylation at individual CpG 
sites demonstrated considerable variability in both IBD subtypes 
compared with controls. A total of 3196 probes were differentially 
methylated (Bonferroni-adjusted p value <0.05) between CD cases 
and controls (Figure 1A). Table 1 shows the 10 top-ranked DMPs 
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and all Bonferroni-significant DMPs are listed in Supplementary 
Table S2. The top-ranked DMP, cg16176675, located in the 5ʹ-UTR 
of the protein-coding TRAF interacting gene (TIFAB), was hyper-
methylated in CD cases compared with controls (mean Δβ = 0.092, 
Bonferroni-adjusted p value [padjusted] 5.86e
-17). Gene ontology (GO) 
enrichment analysis identified 104 FDR-corrected significantly 
enriched terms for the DMPs identified in CD vs control analysis 
(Supplementary Table S3). The most enriched pathways included 
immune response (GO:0006955, q = 1.14e-05), regulation of T cell 
activation (GO:0050863, q = 0.0001) and cellular response to mol-
ecules of bacterial origin (GO:0071219, q = 0.0037).
When UC patients were compared with controls, 1481 probes 
were significantly (padjusted < 0.05) differentially methylated (Figure 1B). 
Table 2 shows the 10 top-ranked DMPs while all Bonferroni signifi-
cant DMPs are listed in Supplementary Table S4. The top-ranked 
DMP was again cg16176675 (TIFAB) and was hypermethylated in 
UC cases compared with controls (mean Δβ = 0.084, padjusted = 2.19e 
-11). GO enrichment analysis identified 2 FDR-corrected significantly 
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Figure 1. DNA methylation changes are widespread in inflammatory bowel disease (IBD) subtypes compared with controls. (A) Manhattan plots showing the 
distribution of p values from the comparison of Crohn’s disease (CD) with controls and the distribution of Bonferroni-significant CD-associated differentially 
methylated positions (DMPs) across genomic features. (B) Manhattan plots showing the distribution of p values from the comparison of ulcerative colitis (UC) 
with controls and the distribution of Bonferroni UC-associated DMPs across genomic features. The top-ranked DMP for both UC and CD is cg16176675 (TIFAB). 
The horizontal red line corresponds to significance after Bonferroni correction. Compared with the genome average, both CD- and UC-associated DMPs are 
under-represented in CpG islands but more frequently present in enhancer regions and gene bodies. (C) Correlations between CD-associated changes in DNA 
methylation (∆β) at 3196 Bonferroni-significant DMPs compared with UC-associated differences at the same probes.
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enriched terms for DMPs identified in UC vs control analysis 
(Supplementary Table S5). The most enriched GO categories were 
related to immune response (GO:0006955, q = 0.03) and small-mol-
ecule catabolic processes (GO:0044282, q = 0.04).
3.2. DNA methylation profiling demonstrates the 
absence of major epigenetic differences between 
CD and UC
There was considerable overlap in UC- and CD-associated DMPs, 
with 1443 (97%) of the UC-associated DMPs also differentially 
methylated in CD. Thirty-eight UC DMPs (3%) were differentially 
methylated in UC only. In contrast, 1753 CD DMPs (55%) were 
unique CD-associated DMPs. The ∆β values of CD-associated DMPs 
were strongly correlated (r = 0.99, p < 0.0001) with UC-associated 
differences at the same probes compared with controls (Figure 1C).
3.3. IBD-associated differentially methylated 
regions
Region-level analysis was performed using Comb-p software to 
identify differentially methylated regions of the genome associated 
with UC and CD compared with controls. Our analysis identified 
2 differentially methylated regions (DMRs) in the UC vs control 
analysis and 7 DMRs in the CD vs control analysis (Table 3). Of 
note, the 2 UC-associated DMRs were also associated with CD. For 
example, we identified an IBD-associated DMR (spanning 11 CpG 
sites) in the promoter region of the TRIM39-RPP21 protein-coding 
gene, which also overlaps the third exon of TRIM39 (Figure 2A). 
Table 1. Top 10 ranked differentially methylated positions in Crohn’s disease (n = 88) compared with controls (n = 39).
Probe ID Mean ∆β p value Adjusted p Hg19 Illumina annotation Probe type Gene annotation from GREAT
(distance from TSS)
cg16176675 0.092 1.36e-22 5.86e-17 Chr5: 134786942 TIFAB II C5orf20 (–3905)
cg21442182 0.092 5.49e-22 2.36e-16 Chr13: 31446420 II ALOX5AP (+158806), HSPH1 
(+289696)
cg10311161 0.102 4.04e-21 1.74e-15 Chr8: 68110902 ARFGEF1 II CSPP1 (+134300), ARFGEF1 
(+145009)
cg17579089 0.090 7.32e–21 3.15e-15 Chr3: 47269695 KIF9 I SETD2 (–64229), KIF9 (+54641)
cg05025332 0.103 1.20e–20 5.17e–15 Chr2: 65165160 II SERTAD2 (–284115), SLC1A4 
(–51334)
cg20061654 0.081 2.43e–20 1.05e–14 Chr22: 45608492 C22orf9 II UPK3A (–72375), NUP50 (+48767)
cg10154880 0.125 2.55e–20 1.10e–14 Chr7: 98603502 TRRAP II TRRAP (+127390), SMURF1 
(+138240)
cg21935981 0.075 5.36e–20 2.31e–14 Chr22: 45608465 C22orf9 II UPK3A (–72402), NUP50 (+48740)
cg22013370 0.105 5.87e–20 2.53e–14 Chr1: 241981543 II OPN3 (–177843), EXO1 (–29949)
cg05921138 0.102 6.11e–20 2.63e–14 Chr2: 121440849 SORL1 I SORL1 (+117938), BLID (+546073)
Adjusted p, Bonferroni-corrected p value; Hg19, Human Genome version 19; GREAT; Genomic Regions Enrichment of Annotations Tool; TSS, transcription 
start site.
Table 2. Top 10 ranked differentially methylated positions in ulcerative colitis (n = 61) compared with controls (n = 39).
Probe ID Mean ∆β p value Adjusted p Hg19 Illumina annotation Probe type Gene annotation from GREAT
(distance from TSS)
cg16176675 0.084 5.07e–17 2.19e–11 Chr5: 134786942 TIFAB II C5orf20 (–3905)
cg02619001 0.075 3.46e–16 1.49e–10 Chr17: 47592333 NGFR II NXPH3 (–60964), NGFR (+19679)
cg07795766 0.051 1.84e–15 7.95e–10 Chr22: 45608516 C22orf9 I UPK3A (–72351), NUP50 (+48791)
cg21935981 0.068 2.38e–15 1.02e–09 Chr22: 45608465 C22orf9 I UPK3A (–72402), NUP50 (+48740)
cg20061654 0.074 2.67e–15 1.15e–09 Chr22: 45608492 C22orf9 I UPK3A (–72375), NUP50 (+48767)
cg23320499 –0.077 5.76e–15 2.48e–09 Chr12: 12659177 DUSP16 II MANSC1 (–156009), DUSP16 (+56270)
cg04223044 0.072 6.67e–15 2.87e–09 Chr22: 45608428 C22orf9 II UPK3A (–72439), NUP50 (+48703)
cg19380303 0.082 7.60e–15 3.27e–09 Chr15: 90172193 KIF7 I KIF7 (+26488), C15orf42 (+53376)
cg04407417 0.041 7.81e–15 3.36e–09 Chr12: 52228651 II FIGNL2 (–2951)
cg10311161 0.086 1.05e–14 4.51e–09 Chr8: 68110902 ARFGEF1 II CSPP1 (+134300), ARFGEF1 (+145009)
Adjusted p, Bonferroni-corrected p value; Hg19, Human Genome version 19; GREAT, Genomic Regions Enrichment of Annotations Tool; TSS, transcription start site.
Table 3. Comb-p differentially methylated region analysis.
Region CpG sites 
in region
 p value Adjusted p 
value
CD-associated DMRs
 Chr1: 2230601–2230924 4 7.66e–12 2.09e–06
 Chr14: 24540174–24540453 4 3.44e–09 0.001087
 Chr11: 65546988–65547173 4 1.02e–08 0.004868
 Chr2: 128458240–128458402 5 5.18e–25 2.82e–19
 Chr6: 6588693–6589076 5 1.11e–16 2.56e–11
 Chr22: 45608345–45608714 10 3.60e–15 8.50e–10
 Chr6: 30297174–30297628 11 1.88e–18 3.65e–13
UC-associated DMRs
 Chr2: 128458240–128458402 5 9.30e–13 5.07e–07
 Chr6: 30297257–30297628 10 2.61e–11 6.21e–06
CD, Crohn’s disease; UC, ulcerative colitis.
p value, slk-corrected p value; Adjusted p value, one-step Šidák multiple-
testing correction.
Differentially methylated regions associated with IBD are highlighted in bold.
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This IBD-associated DMR was hypomethylated across all CpG sites 
in IBD cases compared with controls (Figure 2B).
3.4. DNA methylation differences, disease activity 
and biologic therapy
A number of CpG sites were nominally significantly (p < 0.05) dif-
ferentially methylated in active IBD compared with inactive disease 
(Supplementary Figure S2). However, no DMP remained significant 
after Bonferroni correction for multiple testing. The 10 top-ranked 
DMPs are shown in Table  4. The top-ranked DMP, cg11971248, 
is located in the gene body of the 4-hydroxybenzoate polyprenyl-
transferase (COQ2) gene in a region associated with transcriptional 
activation (mean Δβ = 0.01, p = 1.79e–06). We also assessed the top 
10 DMPs to determine whether there were differences associated 
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Figure 2. Inflammatory bowel disease (IBD)-associated differentially methylated region (DMR) TRIM39-RPP21. (A) A zoomed-in Manhattan plot illustrating the TRIM39 
chromosomal regions. The 11 IBD-associated probes present in the DMR are highlighted in red. Green bars denote the location of an annotated nearby CpG island. Of 
note, the IBD-associated DMR overlaps a promoter region associated with the fusion gene TRIM39-RPP21. (B) DNA methylation levels (β values) are illustrated for each 
sample in the adult IBD blood cohort. All 11 CpG sites are hypomethylated in adult IBD cases compared with controls. (C) DNA methylation levels are illustrated for each 
sample in the paediatric UC and control cohort. All 9 CpG sites are significantly hypomethylated in paediatric UC cases compared with controls. Lines represent average 
CpG methylation across each sample in each group (disease, red; controls, blue). *****p < 1e–07; ****p < 1e–06; *** p < 1e–05; **p < 1e–04; *p < 1e–03.
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with the use of biologic therapy. No differences were found between 
the two groups (data not shown).
3.5. TRAF6 technical validation and gene 
expression analysis
Technical validation of the 450K DNA methylation results was 
performed by pyrosequencing the TRAF6 CpG site, cg01476222. 
We studied TRAF6 because it was hypermethylated in both CD 
and UC compared with controls (∆β  =  0.10, padjusted  =  1.52e
–11; 
∆β = 0.09, padjusted = 6.59e
–08) and is a key component of important 
immune response pathways, including NF-κB and TNF signalling. 
Bisulphite pyrosequencing of TRAF6 strongly correlated with our 
Illumina 450K DNA methylation results (r  =  0.88, p  <  0.0001, 
Figure  3A) and confirmed DNA hypermethylation in IBD cases 
compared with controls at this locus (p < 0.001, Figure 3B). We 
also examined mRNA levels of TRAF6 in a sub-cohort of IBD 
patients (n  = 63) and controls (n  = 20). TRAF6 gene expression 
was downregulated in IBD patients compared with controls, con-
sistent with our finding of DNA hypermethylation at this region 
(Figure 3B and C).
3.6. Investigating top-ranked IBD-associated DMPs 
in colonic mucosa from treatment-naive paediatric 
IBD cases
We examined DNA methylation at the top-ranked IBD-associated 
DMP (cg16176675, TIFAB) and at cg01476222, TRAF6 in colonic 
mucosa from treatment-naive paediatric IBD cases and control sam-
ples (24 IBD cases [15 CD and 9 UC]) and 22 controls. The top-
ranked IBD-associated DMP (cg16176675, TIFAB) was found to be 
significantly differentially methylated in paediatric colonic mucosal 
samples in patients with UC (mean ∆β = –0.06, q = 5.60e–06) and CD 
(mean ∆β = –0.03, q = 0.05) compared with controls. Meanwhile, 
the TRAF6-associated DMP was significantly differentially meth-
ylated in UC cases compared with controls (mean ∆β  =  –0.12, 
q  =  0.005) but not in CD cases compared with controls (mean 
∆β = –0.05, q = 0.21). Both DMPs were hypomethylated in colonic 
mucosa in paediatric IBD cases compared with controls, in contrast 
to our findings in PBMCs obtained from adult IBD patients, which 
showed evidence of hypermethylation compared with controls. In 
addition, the methylation status of 11 CpG sites in the TRIM39-
RPP21 gene identified in our regional analysis was also examined in 
colonic mucosa from paediatric IBD cases. DNA methylation data 
were available for 9 of the 11 CpG sites and all 9 CpG sites were 
significantly hypomethylated in colonic mucosa from treatment-
naive paediatric UC (but not CD) cases compared with controls 
(Figure 2C).
4. Discussion
This study has identified numerous site-specific changes in DNA 
methylation in genes that have not been widely described in IBD, 
but are associated with pathways that are integral to the disorder. 
The top-ranked DMP (cg16176675) was significantly hypermeth-
ylated in both CD and UC cases compared with controls. This 
IBD-associated DMP is located in the 5ʹ-UTR of protein coding 
gene, TIFAB (TRAF-interacting protein with forkhead-associated 
domain, family member B). TIFAB, by inducing a conformational 
change in TIFA (TRAF-interacting protein with a forkhead-associ-
ated domain), limits the interaction between IRAK1 and TRAF6.29 
Interestingly, the same CpG site was also significantly differentially 
methylated in colonic mucosa samples of treatment-naive paediatric 
IBD patients compared with controls. Of note, we observed DNA 
hypermethylation at this locus in adult IBD patients in contrast to 
the DNA hypomethylation observed in the colonic mucosa samples 
of paediatric patients. It is possible, therefore, that while aberrant 
DNA methylation at this locus is associated with IBD pathogenesis, 
methylation patterns and potential regulation of this locus differs 
between adult and paediatric IBD or between blood and mucosal 
samples. Of note, comparison of the top-ranked DMPs and the 
TRIM39-RPP21 DMR identified in this study with previous DNA 
methylation studies in adult cohorts of IBD11,12 patients was not pos-
sible; these studies performed DNA methylation profiling using the 
HumanMethylation27 DNA methylation array, which only covers a 
small subset of the CpG sites covered by the HumanMethylation450 
BeadChip array used in this study. The HumanMethylation27 DNA 
methylation array does not cover DMPs TIFAB (cg16176675) and 
TRAF6 (cg01476222) and the TRIM39-RPP21 DMR. However, 
further epigenetic profiling in clearly defined adult and paediatric 
cohorts in both CD and UC in multiple different nationalities is 
required to confirm the validity of our results and their relevance to 
other populations.
In this study, we found considerable overlap between UC and CD 
DMPs, with 45% of CD-associated DMPs also differentially meth-
ylated in UC and 97% of UC DMPs also differentially methylated 
in CD. These data indicate that, similar to genetic findings in IBD, 
Table 4. Top 10 ranked differentially methylated positions (DMPs) in 149 patients comparing active (n = 79) with inactive (n = 70) inflam-
matory bowel disease.
Probe ID Mean ∆β p value Adjusted p Hg19 Illumina annotation Probe type Gene annotation from GREAT
(distance from TSS)
cg11971248 0.011 1.79e–06 0.771 Chr4: 84203337 COQ2 II COQ2 (+2729), COPS4 (+247099)
cg26455541 0.007 2.48e–06 1 Chr4: 26321238 RBPJ I RBPJ (–1190)
cg10724442 0.004 2.87e–06 1 Chr19: 40971809 SPTBN4; BLVRB I SPTBN4 (–1316), BLVRB (–85)
cg21494337 0.006 2.88e–06 1 Chr2: 25015597 CENPO; C2orf79 II CENPO (–733), PTRHD1 (+653)
cg15613012 –0.010 3.40e–06 1 Chr6: 28887742 TRIM27 II SCAND3 (–332631), TRIM27 (+4025)
cg21218864 0.017 3.41e–06 1 Chr1: 206730120 RASSF5 II RASSF5 (+49242), EIF2D (+55783)
cg17440044 0.017 4.05e–06 1 Chr7: 100167198 II SAP25 (+4071), AGFG2 (+30365)
cg22380652 0.006 4.57e–06 1 Chr1: 43389667 II SLC2A1 (+35179), ZNF691 (+77424)
cg27386912 0.007 4.64e–06 1 Chr3: 52479108 SEMA3G II SEMA3G (–66)
cg02712401 0.004 5.60e–06 1 Chr12: 6961946 USP5; CDCA3 II CDCA3 (–1491), USP5 (+662)
Adjusted p; Bonferroni corrected p value; Hg19, Human Genome version 19; GREAT, Genomic Regions Enrichment of Annotations Tool; TSS, transcription 
start site.
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where several of the described loci are common to both diseases, a 
large number of the epigenetic disease associations may be shared by 
the IBD subgroups.1 A DNA methylome study of colonic mucosal 
biopsies of paediatric IBD patients also reported significant over-
lap (53.7%) between CD-associated and UC-associated DMRs.13 
Furthermore, a meta-analysis of whole-genome transcriptional 
profiling of IBD colon mucosa described an absence of major tran-
scriptional differences between CD and UC.30 However, GO enrich-
ment analysis in CD implicated pathways associated with both 
adaptive and innate immunity (e.g. T cell regulation) in contrast to 
UC, which highlighted those associated with innate responses only 
(e.g. cellular response to lipopolysaccharide and cellular response to 
molecules of bacterial origin). These data suggest that while distinct 
patterns of immune dysregulation occur, overall the epigenetic archi-
tecture appears similar.
Although the majority of top-ranked disease-associated DMPs 
identified in this study are hypermethylated compared with con-
trols overall, there is no bias towards either hypermethylation or 
hypomethylation at significant DMPs in this study (Supplementary 
Figure 3). Several of the top-ranked UC- and CD-associated DMPs 
were located in the vicinity of genes involved in pathways impli-
cated in IBD. For example, cg01476222, located in the gene body 
of TRAF6, was hypermethylated in both UC and CD. TRAF6 
mediates signal transduction downstream of the TNF recep-
tor superfamily as well as the Toll/IL-1 family.31 We confirmed 
DNA methylation levels at the cg01476222 (TRAF6) locus in 
IBD cases and controls by bisulphite pyrosequencing. Our results 
strongly correlated with DNA methylation levels obtained from 
the Illumina 450K BeadChip array; this is consistent with previous 
studies.32,33,34,35 Furthermore, we found a significant reduction in 
TRAF6 mRNA expression in cases compared with controls, indi-
cating that hypermethylation at this locus coincides with reduced 
mRNA expression. To the best of our knowledge, this is the first 
report implicating aberrant DNA methylation and gene expression 
of TRAF6 in the pathogenesis or pathology of IBD. A recent study 
showing that mice lacking Traf6 have exacerbated dextran sodium 
sulphate-induced colitis corroborates our findings.36 Interestingly, 
we found that the same CpG site is significantly differentially meth-
ylated in colonic mucosa samples from treatment-naive paediatric 
UC patients compared with control subjects but in the opposite 
direction, suggesting that while aberrant DNA methylation at 
this locus is associated with IBD pathogenesis, DNA methylation 
patterns and potential regulation of this locus differ in adult and 
paediatric IBD. Future work evaluating both DNA methylation 
and gene expression changes in TRAF6 in a larger cohort of IBD 
patients and controls is warranted to evaluate its potential as a 
diagnostic biomarker or therapeutic target for IBD.
In addition to identifying site-specific disease-associated changes 
in DNA methylation, identification of regional DNA methyla-
tion variations may also be important. Our region-level analysis 
identified an IBD-associated DMR (spanning 11 CpG sites) in the 
promoter region of the TRIM39-RPP21 protein-coding gene and 
overlapping the third exon of TRIM39. TRIM39-RPP21 encodes 
a putative PKGI-interactor that is a novel variant of TRIM39.37 
TRIM39-RPP21 regulates the type I interferon pathway and is thus 
important in regulation of viral immunity.38 This IBD-associated 
DMR was also significantly hypomethylated in colonic mucosa 
from paediatric UC patients. Interestingly, TRIM39 gene expres-
sion is significantly increased in both CD (log2 fold change = 0.175, 
corrected p value = 0.03) and UC (log2 fold change = 0.161, cor-
rected p value = 0.0002) compared with controls in a whole-genome 
gene expression analysis of IBD colon mucosa.30 DNA methylation 
changes in this region could potentially have a regulatory role in 
both TRIM39 and TRIM39-RPP21 gene expression and/or splicing 
of this locus, warranting further investigation in larger cohorts of 
adult and paediatric IBD patients to help understand its potential 
role in disease pathology. Of note, due to limitations in the design 
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Figure 3. TRAF6 is hypermethylated and expression is reduced in peripheral 
blood mononuclear cells (PBMCs) of patients with inflammatory bowel 
disease (IBD) compared with healthy controls. (A) Bisulphite pyrosequencing 
of TRAF6 confirmed our Illumina 450K DNA methylation results. The β value 
for cg01476222 (TRAF6, intron 2) obtained from the Illumina 450K analysis 
was strongly correlated with DNA methylation levels of this CpG site 
obtained by pyrosequencing. Correlation was assessed using Spearman’s 
test. (B) TRAF6 DNA methylation (determined by pyrosequencing) was 
significantly increased in the PBMCs of patients with IBD (n = 146) compared 
with healthy controls (n = 35). Boxes represent interquartile ranges and error 
bars 95th centiles. (C) RNA was isolated from patient (n = 63) and control 
(n = 20) PBMCs and TRAF6 expression was analysed by real-time PCR. ∆Ct 
was calculated relative to 18s. TRAF6 expression was significantly reduced 
in IBD patient samples compared with controls. Boxes represent interquartile 
ranges and error bars 95th centiles. ***p < 0.001, Mann–Whitney U test.
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of the 450K array, which contains sparsely represented areas of the 
genome, it is plausible that other disease-associated DMRs may not 
have been captured by the method used in this study.
The precise factors that lead to IBD development remain 
unknown, as do the molecular changes associated with disease 
recurrence and activity. We therefore examined genome-wide DNA 
methylation changes in patients with active and inactive IBD. We 
observed no statistically significant changes in DNA methylation in 
active IBD compared with inactive disease. However, a number of 
the top-ranked active disease-associated DMPs are associated with 
genes that have previously been implicated in IBD susceptibility. 
For example, cg26455541, which is hypermethylated in active IBD 
compared with inactive disease, is located in RBPJ. Mice harbour-
ing IEC-specific deletion of Rbpj (RBP-JΔIEC) spontaneously develop 
chronic colitis.39 Further, larger studies assessing disease activity 
would be valuable in defining the association between activity and 
DNA methylation changes that may occur during disease progres-
sion and regression.
Our study does have several caveats. Firstly, methylation pro-
filing was performed on PBMCs rather than on mucosal samples. 
However, it is well established that IBD is associated with sys-
temic inflammation and it is therefore plausible that disease-related 
changes in DNA methylation can be identified in peripheral blood. 
Furthermore, in this study we confirmed IBD-associated differ-
ential methylation of 2 of  top-ranked DMP (cg23933044) and 
DMP (cg01476222) and top-ranked DMR (TRIM39-RPP21) using 
colonic mucosal samples, indicating that locus-specific methylation 
patterns identified in peripheral tissue can reflect DNA methylation 
patterns in disease-related tissue. Moreover, the colonic samples we 
used were taken from treatment-naive cases, suggesting that changes 
in DNA methylation at these loci are not a consequence of IBD-
related treatments. Although further comparison studies are neces-
sary in paired mucosal and haematological tissues, our data indicate 
that easily accessible peripheral tissues, such as PBMCs, may have 
potential as candidate biomarkers for IBD in the future. A further 
caveat is that our study group included both CD and UC patients 
with varying degrees of disease activity as measured using a combi-
nation of clinical, biological and endoscopic variables. In addition, 
our study group was heterogeneous with regard to disease location, 
biologic use and disease duration. However, this heterogeneous 
cohort allowed us to determine epigenetic similarities and differ-
ences between those with CD and UC, and also compare DNA meth-
ylation profiles of patients with active and inactive IBD. We found no 
statistically significant epigenetic differences between patients with 
active or inactive disease or on biologic therapies. However, larger, 
more powerful studies on more homogeneous patient populations 
with respect to disease duration, disease location and other clinical 
features will be required to tease out these associations more thor-
oughly. A final comment is that RNA was only available for a sub-
cohort of samples and thus we could only assess the functional effect 
of DNA methylation at one locus, TRAF6. Nevertheless, our results 
provide the impetus for future studies that aim to integrate methyl-
omic findings with transcriptional profiles in large-scale IBD cohorts.
Overall, we present strong evidence that epigenetic variation is 
associated with IBD and that differences in DNA methylation can be 
identified in peripheral blood DNA samples. We identified numer-
ous significant site-specific and regional changes in DNA methyla-
tion in genes associated with pathways integral to IBD pathogenesis, 
including TRIM39-RPP21 and TRAF6, which were hypomethylated 
and hypermethylated, respectively, in both UC and CD. Moreover, 
TRAF6 mRNA expression was reduced in IBD cases compared to 
controls, suggesting that hypermethylation at this locus coincides 
with reduced gene expression. Finally, there was considerable over-
lap between UC and CD DMPs. These findings are consistent with 
previous transcriptional and genetic findings in IBD, indicating a 
considerable overlap between CD and UC molecular pathology.
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